Back to results

RecruitingPhase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Clinical Site

Phoenix, Arizona, United States

+25 additional locations

Contact

Clinical Trials Contact Center

+1 650 839 4380 ML-007C-MA-ADP@maplightrx.com

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2025-08-15
Enrollment: 300 participants
Sponsor: MapLight Therapeutics
Purpose: treatment

Locations (26)

Clinical SitePhoenix, Arizona, United States
Clinical SiteScottsdale, Arizona, United States
Clinical SiteTucson, Arizona, United States
Clinical SiteAnaheim, California, United States
Clinical SiteOrange, California, United States
Clinical SiteSan Diego, California, United States
Clinical SiteBoca Raton, Florida, United States
Clinical SiteDeerfield Beach, Florida, United States
Clinical SiteDoral, Florida, United States
Clinical SiteHomestead, Florida, United States
Clinical SiteMiami, Florida, United States
Clinical SiteMiami, Florida, United States
Clinical SiteMiami, Florida, United States
Clinical SiteMiami, Florida, United States
Clinical SiteMiami Gardens, Florida, United States
Clinical SiteMiami Gardens, Florida, United States
Clinical SiteNaples, Florida, United States
Clinical SiteOrlando, Florida, United States
Clinical SiteWest Palm Beach, Florida, United States
Clinical SiteLas Vegas, Nevada, United States
Clinical SiteWest Long Branch, New Jersey, United States
Clinical SiteIndependence, Ohio, United States
Clinical SiteBrampton, Ontario, Canada
Clinical SiteLondon, Ontario, Canada
Clinical SiteToronto, Ontario, Canada
Clinical SiteLévis, Quebec, Canada

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis — TrialFind